Showing results (171-180 of 190) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancerA W Tolcher, K H Cowan, D Solomon, et al.JCO Oncology Practice|June 25, 2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Hope S Rugo, Mina S Sedrak, et al.The New England Journal of Medicine|September 16, 2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerAditya Bardia, Xichun Hu, Rebecca Dent, et al.The Science of the Total Environment|September 5, 2024
Ecosystem engineers enhance the multifunctionality of an urban novel ecosystem: Population persistence and ecosystem resilience since the 1980sLouise B Firth, Anastasia Forbes, Antony M Knights, et al.European Journal of Cancer (Oxford, England : 1990)|November 15, 2022
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancerSibylle Loibl, Delphine Loirat, Sara M Tolaney, et al.NPJ Breast Cancer|July 20, 2017
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant populationTimothy R Wilson, Jianjun Yu, Xuyang Lu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerStephen E Jones, Michael A Savin, Frankie Ann Holmes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2017
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast CancerMariaelena Pierobon, Corinne Ramos, Shukmei Wong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulatorCarol J Fabian, Bruce F Kimler, Julie Anderson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])Charles E Geyer, Joanne L Blum, Greg Yothers, et al.Pageof 19